Mark Vachon Net Worth

The estimated Net Worth of Mark Vachon is at least $2.2 Million dollars as of 4 June 2018. Mr. Vachon owns over 6,000 units of Bluebird bio Inc stock worth over $4,060 and over the last 10 years he sold BLUE stock worth over $1,706,470. In addition, he makes $485,636 as Independent Director at Bluebird bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Vachon BLUE stock SEC Form 4 insiders trading

Mark has made over 5 trades of the Bluebird bio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of BLUE stock worth $189,990 on 14 June 2018.

The largest trade he's ever made was selling 7,000 units of Bluebird bio Inc stock on 11 December 2017 worth over $1,516,480. On average, Mark trades about 1,625 units every 17 days since 2014. As of 4 June 2018 he still owns at least 7,000 units of Bluebird bio Inc stock.

You can see the complete history of Mr. Vachon stock trades at the bottom of the page.

Mark Vachon biography

Mark Vachon serves as Independent Director of the Company. Mr. Vachon is a Class I director who has served as a member of our Board of Directors since July 2014. Mr. Vachon served as an Executive Vice President Sales, Integration and Operations at Change Healthcare Holdings, Inc. from November 2016 to April 2018. For over 30 years, Mr. Vachon held a variety of leadership positions across the General Electric organization, and was a company officer beginning in 1999 and a member of GE’s Corporate Executive Council. Mr. Vachon was President and CEO of GE Healthcare Americas from 2009 and 2010, and prior to that he was President and CEO of Global Diagnostics Imaging, GE Healthcare, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was Executive Vice President and CFO of GE Healthcare. Mr. Vachon serves on the board of trustees of Northeastern University and the Board of Directors of Numotion, and the Charitable Health and Retirement Trust. Mr. Vachon holds a B.S. in Finance from Northeastern University and an M.A. from Boston College.

What is the salary of Mark Vachon?

As the Independent Director of Bluebird bio Inc, the total compensation of Mark Vachon at Bluebird bio Inc is $485,636. There are 11 executives at Bluebird bio Inc getting paid more, with Nick Leschly having the highest compensation of $13,153,600.

How old is Mark Vachon?

Mark Vachon is 61, he's been the Independent Director of Bluebird bio Inc since 2014. There are 3 older and 19 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.

What's Mark Vachon's mailing address?

Mark's mailing address filed with the SEC is 60, Binney Street, East Cambridge, Cambridge, Middlesex County, Massachusetts, 02142, United States.

Insiders trading at Bluebird bio Inc

Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore und Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.

What does Bluebird bio Inc do?

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Complete history of Mr. Vachon stock trades at Bluebird bio Inc

Bluebird bio Inc executives and stock owners

Bluebird bio Inc executives and other stock owners filed with the SEC include:

• Nick Leschly,
  President, Chief Executive Officer, Director
• William Baird,
  Chief Financial Officer
• David Davidson,
  Chief Medical Officer
• Philip Gregory,
  Chief Scientific Officer
• Jason Cole,
  Chief Operating Officer and Legal Officer, Secretary
• Nick Leschly,
  Pres & Director
• William Sellers,
  Independent Director
• William D. Baird III,
  Principal Financial & Accounting Officer
• Daniel Lynch,
  Independent Chairman of the Board
• Jason F. Cole Esq.,
  Chief Strategy & Financial Officer
• Thomas J. Klima,
  Chief Commercial Officer & COO
• Mark Vachon,
  Independent Director
• David Schenkein,
  Independent Director
• Wendy Dixon,
  Independent Director
• John Agwunobi,
  Independent Director
• Ingrid Goldberg,
  VP, Investor Relations
• Denice Torres,
  Director
• Joanne Smith-Farrell,
  Chief Business Officer
• Alison Finger,
  Chief Commercial Officer
• Katy Burnett,
  Interim Principal Accounting Officer
• Richard Colvin M.D., Ph.D.,
  Chief Medical Officer
• Andrea Walton,
  Chief People Officer
• Katherine Edna Breedis C.F.A., CMT,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Anne-Virginie Eggimann M.Sc.,
  Chief Regulatory Officer
• Melissa Bonner,
  Sr. VP of Research
• Dr. Liviu Niculescu M.D., Ph.D.,
  Sr. VP of Global Medical Affairs
• Sarah Alspach,
  Chief Communications Officer
• Kathleen A. Wilkinson,
  Chief People Officer
• Elizabeth Pingpank,
  Director of Corp. Communications
• Helen C. Fu,
  Sr. VP, Gen. Counsel & Sec.
• Jessica Whitten,
  VP, Global Controller & Chief Accounting Officer
• Kasra Kasraian,
  Sr. VP of Technical Devel. & Operations
• Gina R. Consylman CPA,
  Chief Financial Officer
• Andrew Obenshain,
  Pres, CEO & Director
• John Maraganore,
  Director
• James Mandell,
  Director
• Susanna Gatti High,
  Chief Operating Officer
• Eric Sullivan,
  Principal Accounting Officer
• Andrew Obenshain,
  President and CEO
• Douglas Melton,
  
• Mary Lynne Hedley,
  Director
• Kory James Wentworth,
  Principal Accounting Officer
• Thomas J Klima,
  See Remarks
• Charlotte Jones Burton,
  
• Axel Polack,
  Director
• Geert Jan Mulder,
  Director
• Christopher Krawtschuk,
  Chief Financial Officer
• Mitchell H. Finer,
  Chief Scientific Officer
• James M. Detore,
  Chief Financial Officer
• Venture Fund Vii Lparch Ven...,
  
• Robert I Tepper,
  Director
• Rock Ventures Lptrv Gp, Llc...,
  
• Linda Bain,
  VP, Fin. & Business Operations
• Rock Ventures Lp Third Rock...,
  
• Jeffrey T. Walsh,
  Chief Strategy Officer
• Steven Gillis,
  Director
• Richard A. Paulson,
  
• Gina Consylman,
  Chief Financial Officer
• Anne Virginie Eggimann,
  Chief Regulatory Officer
• Jessica Whitten,
  Chief Accounting Officer
• Marcela V. Maus,
  Director
• Sarah Js Glickman,
  Director
• Ramy Ibrahim,
  Director
• Joseph Vittiglio,
  Chief Business & Legal Officer
• Richard A Colvin,
  Chief Medical Officer
• Najoh Tita Reid,
  
• Elisabeth Leiderman,
  
• Michael Cloonan,
  
• O. James Sterling,
  Chief Financial Officer